CRS, ICANS Rare After 2 Weeks of CAR T-Cell Therapy New-onset ICANS from days 8 to 14 after CAR T-cell infusion occurred in 9 3% of patients overall, 19% of axi-cel recipients, 9% of liso-cel recipients, and 1% of tisa-cel recipients (P < 0001)
Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R R CLL SLL A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL SLL The following
Breyanzi Approved for Relapsed Refractory Follicular Lymphoma The US Food and Drug Administration (FDA) has granted accelerated approval to Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adults with relapsed or refractory follicular